IE
NKTR icon

Israel Englander’s Nektar Therapeutics NKTR Stock Holding History

Israel Englander’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Buy
+170,000
New +$12.4M ﹤0.01% 2111
2025
Q4 		– Sell
-25,000
Closed -$1.42M – 6313
2025
Q3 		$1.42M Sell
25,000
-54,000
-68% -$1.79M ﹤0.01% 4341
2025
Q2 		$2.04M Buy
+79,000
New +$887K ﹤0.01% 3859
2022
Q2 		– Sell
-52,773
Closed -$4.27M – 7317
2022
Q1 		$4.27M Buy
52,773
+32,146
+156% +$4.76M ﹤0.01% 3105
2021
Q4 		$4.18M Buy
+20,627
New +$4.47M ﹤0.01% 3091
2021
Q1 		– Sell
-6,667
Closed -$1.7M – 6329
2020
Q4 		$1.7M Buy
+6,667
New +$1.72M ﹤0.01% 3369
2018
Q4 		– Sell
-5,000
Closed -$4.57M – 4043
2018
Q3 		$4.57M Buy
+5,000
New +$4.27M 0.01% 1873
2018
Q1 		– Sell
-2,200
Closed -$1.97M – 3936
2017
Q4 		$1.97M Buy
+2,200
New +$1.3M ﹤0.01% 2296
2017
Q2 		– Sell
-13,333
Closed -$4.69M – 3725
2017
Q1 		$4.69M Buy
+13,333
New +$3M 0.01% 1491
2013
Q4 		– Sell
-70,040
Closed -$11M – 3665
2013
Q3 		$11M Buy
70,040
+29,887
+74% +$5.53M 0.04% 632
2013
Q2 		$6.96M Buy
+40,153
New +$6.16M 0.02% 826

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's NKTR Position: Q2 2026 in Review

Israel Englander increased its Nektar Therapeutics (NKTR) stake by 18% in Q2 2026, buying an estimated $5.4M and bringing the position to 478,120 shares worth $33.4M. The position accounts for 0.01% of the portfolio, ranked #1192.

Israel Englander first reported a position in NKTR in Q2 2013 and has held it in 46 quarters since. The position peaked at $114M in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Israel Englander held 478,120 shares of Nektar Therapeutics worth $33.4M as of Q2 2026.
  • Israel Englander bought 73,843 Nektar Therapeutics shares in Q2 2026, an estimated $5.4M.
  • Nektar Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1192 holding.
  • Israel Englander first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 46 quarters since.
  • Israel Englander's Nektar Therapeutics position peaked at $114M in Q1 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.